Global Cushing Syndrome Drug Pipeline Market Research Report 2022: Comprehensive Insights About 8+ Companies and 8+ Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Cushing Syndrome - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

This "Cushing Syndrome - Pipeline Insight, 2022" report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Cushing Syndrome pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

A detailed picture of the Cushing Syndrome pipeline landscape is provided which includes the disease overview and Cushing Syndrome treatment guidelines. The assessment part of the report embraces, in depth Cushing Syndrome commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence in Cushing Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve in Cushing Syndrome.

In May, 2021 Sparrow Pharmaceuticals presented new data of SPI-62 trial. SPI-62 is a potent and selective HSD-1 inhibitor, has demonstrated the ability to reduce intracellular cortisol in the liver by 90. Results of four Phase 1 and Phase 2 clinical trials in which SPI-62 was administered to 165 individuals showed, Pharmacokinetics supportive of once-daily oral dosing. Generally good safety and tolerability at and above the anticipated clinical dose.

In August 2021, CRN04894: Crinetics Pharmaceuticals announced positive preliminary findings from the single ascending dose (SAD) portion of a first-in-human Phase 1 clinical study with CRN04894 demonstrating pharmacologic proof-of-concept for this first-in-class, investigational, oral, nonpeptide adrenocorticotropic hormone (ACTH) antagonist that is being developed for the treatment of conditions of ACTH excess, including Cushing's disease and congenital adrenal hyperplasia.

Cushing Syndrome Emerging Drugs

Relacorilant: Corcept Therapeutics

Relacorilant is a non-steroidal, selective glucocorticoid receptor modulator that does not bind to the body's other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders, including ovarian and adrenal cancer and Cushing's syndrome. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents, as well as orphan drug designation in the United States for the treatment of pancreatic cancer and both the United States and the European Union for the treatment of Cushing's syndrome.

SPI-62: Sparrow Pharmaceuticals

SPI-62 is an oral, small molecule, novel 11?-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor. Sparrow's lead proprietary small molecule SPI-62 reduces intracellular cortisol, the main cause of morbidity in Cushing syndrome. SPI-62 was associated with few, mostly mild, adverse effects in four prior clinical trials. In subjects with diabetic peripheral neuropathy, SPI-62 showed clinically meaningful separation from placebo on HbA1c, glucose, cholesterol, and triglycerides.

CRN04894: Crinetics Pharmaceuticals

CRN04894 is a nonpeptide, small molecule that is designed to be taken orally to block the interaction of ACTH with its target receptor. It has the potential to offer a life-saving treatment option to patients with Cushing's disease, CAH and related diseases. Based on encouraging preclinical results, Company initiated a double-blind, randomized, placebo-controlled Phase 1 study of this orally administered, nonpeptide small molecule drug candidate in healthy volunteers. This study will assess the safety and tolerability of single and multiple doses of CRN04894 and will measure the effect of CRN04894 on suppression of cortisol, cortisol precursors, and adrenal androgens following exogenous ACTH stimulation.

Cushing Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Cushing Syndrome drugs segregated based on following parameters that define the scope of the report.

Cushing Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cushing Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cushing Syndrome drugs.

Key Questions Answered

• How many companies are developing Cushing Syndrome drugs?
• How many Cushing Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cushing Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cushing Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cushing Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Strongbridge Biopharma
• Corcept Therapeutics
• Crinetics Pharmaceuticals
• Cyclacel Pharmaceuticals
• Sparrow Pharmaceuticals
• AstraZeneca

Key Products

• Veldoreotide
• Relacorilant
• CRN-04894
• Seliciclib
• SPI-62
• AZD4017

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/dv93su